Skip to main content

Table 3 Identity and amounts of related substances and impurities in seven generic products compared to Madopar®/Prolopa® specifications

From: Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®

Degradation product Ro 04-1419 Ro 08-1580 Ro 04-1419 + Ro 08-1580 Others each Others total
Tablets Upper limits (%) 1.54 2.49 3.49 0.54 1.04
Levodopa/ Benserazid beta 0.35 0.47 0.83 0.19, 0.09 0.28
Levodopa/ Benserazid-CT 0.28 0.48 0.75 0.09, 0.08 0.17
Levodopa/ Benserazide ratiopharm 0.25 0.37 0.62 0.16, 0.05 0.21
dopadura B 0.26 0.34 0.60 0.12 0.12
Capsules Upper limits (%) 0.54 0.54 0.49 0.24 0.54
Levopar 0.12 0.34 0.46 0.10 0.10
Levodopa comp. B STADA 0.16 0.32 0.49 0.11, 0.11 0.11
Levobens-Teva 0.36 0.25 0.62* 0.10, 0.12, 0.10 0.33
  1. *Values marked with an asterisk indicate deviations from Roche specifications.